Immatics N.V. (NASDAQ:IMTX) Given Consensus Rating of “Moderate Buy” by Brokerages

Immatics N.V. (NASDAQ:IMTX) has received an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $19.20.

Several research firms recently weighed in on IMTX. Chardan Capital reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Immatics in a research note on Monday, November 24th. Leerink Partners restated an “outperform” rating and issued a $17.00 price target on shares of Immatics in a research report on Thursday, December 4th. Wall Street Zen raised Immatics from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. Guggenheim boosted their price objective on shares of Immatics from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Finally, Mizuho set a $25.00 price objective on shares of Immatics in a research note on Thursday, February 19th.

Immatics Trading Down 1.6%

Shares of Immatics stock opened at $10.13 on Friday. The company has a 50-day moving average of $9.91 and a two-hundred day moving average of $9.00. Immatics has a 12-month low of $3.30 and a 12-month high of $12.41. The stock has a market cap of $1.23 billion, a PE ratio of -9.93 and a beta of 1.36.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Fox Run Management L.L.C. purchased a new stake in Immatics during the 2nd quarter worth about $136,000. Aberdeen Group plc lifted its holdings in Immatics by 9.7% in the 3rd quarter. Aberdeen Group plc now owns 789,446 shares of the company’s stock valued at $6,726,000 after purchasing an additional 69,860 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Immatics by 28.7% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 31,894 shares of the company’s stock valued at $172,000 after purchasing an additional 7,116 shares in the last quarter. Readystate Asset Management LP acquired a new stake in shares of Immatics during the 3rd quarter worth about $426,000. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in shares of Immatics by 8.3% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 47,635 shares of the company’s stock worth $406,000 after buying an additional 3,666 shares in the last quarter. 64.41% of the stock is currently owned by institutional investors and hedge funds.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.